Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 1 of 20

 
 

Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. Read More 
 
Trailing Twelve Months EPS: $11.36
2024 EPS Estimate: ($0.26)
2025 EPS Estimate: ($6.36)

Current Stock Price
$55.40
P/E Ratio
4.9
Consensus Rating
Moderate Buy
Ratings Breakdown
4 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$52.33 (5.5% Downside)

 

Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)

Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025

Click here to reserve your seat at the Crypto Community Summit.